(Q35068112)

6 August 2017

1 reference

title

Advances in hepatitis B virus infection (English)

1 reference

6 August 2017

1 reference

2

Fung JJ

2 references

ORCID Public Data File 2021

6 August 2017

author name string

Jain AB

series ordinal

1

1 reference

PubMed ID

12591432

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Transplantation Proceedings

6 August 2017

1 reference

6 August 2017

35

1 reference

6 August 2017

1

1 reference

6 August 2017

342-344

1 reference

Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Evolving therapies for the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Lamivudine for hepatitis B after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Lamivudine for the treatment of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Management of viral hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Current pharmacotherapy for hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Clinical potential of emerging new agents in hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Severe clinical course of de novo hepatitis B infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Passive immunization with OMRI-Hep-B for prevention of hepatitis B virus reinfection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Outcome of liver transplantation for hepatitis B: report of a single center's experience

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Comparison of the efficacy in prevention of hepatitis B virus recurrence after liver transplantation between HBIG and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903996-9

7 January 2021

10.1016/S0041-1345(02)03996-9

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12591432